How Has NASP Advocated on Behalf of Specialty Pharmacies in the Fight Against DIR Fees?
March 5th 2018Shiela Arquette, RPh, BS Pharm, Executive Director, National Association of Specialty Pharmacy, discusses how the organization has fought against direct and indirect remuneration fees on behalf of specialty pharmacies.
What are Key Considerations When Launching a Rare Disease Drug in a Specialty-Naive Market?
February 28th 2018Joy Gilbert, Vice President, Operations, US Bioservices, a part of AmerisourceBergen, speaks about the many considerations that have to be addressed when launching a novel rare disease drug in a specialty-naive market.